Finally, the full impact of liquid biopsy
The pioneering science of our founders, combined with over a decade of gene expression research, culminated in critical breakthroughs that allow us to infer gene expression directly from standard circulating tumor DNA (ctDNA) sequencing. This brings a new dimension to minimally invasive blood testing that unlocks deeper, more dynamic biomarker data to power precision oncology.
Our proprietary ExpressCT™ technology manifested in the GenomicsNext™ platform brings the powerful dimension of gene expression to liquid biopsies. Our liquid biopsy technology teases out the DNA regions that are most correlated with tissue expression – enabled by a single genomic assay that delivers deep insight.
Products & the GenomicsNext liquid biopsy platform
Our products are powered by gene expression – through technologies like RNA-seq or ctDNA fragmentomics – to address high unmet medical needs and offer a highly integrative solution to advance cancer genomic profiling.
LEARN MORE
Partner with us
GeneCentric collaborates with world-leading research and development organizations, biopharma companies and commercial labs. Bringing together our unique strengths and proprietary gene expression technology with partner interests, we rapidly and efficiently translate the most promising science and advance drug development to deliver new hope to those fighting cancer.
LEARN MORE